BioCentury

Current Editions

Treating obesity by quelling inflammation in the brain

How NLRP3 inhibitors could extend durability and enhance CV benefits over GLP-1 therapies alone

Product Development

Data Byte

WuXi AppTec report shows CDMO’s integration in U.S. biopharma sector

More than 60% of company’s revenues derived from the U.S.

Politics, Policy & Law

Crowley’s vision for BIO; plus MASH & CAR Ts — a BioCentury podcast

Madrigal prepares to launch its MASH drug. BCMA-directed CAR Ts go before FDA’s ODAC

Deals

Deals Report: AZ buys Amolyt for Phase III asset, Novartis takes out IFM Due

Plus: Merck gains access to Pearl Bio’s synthetic biology platform for up to $1B, Hansoh partners with Biotheus on bispecific ADCs, and more

Management Tracks

Syndax names new commercial head

Plus: Everest hires Sandra Zeng as CMO and Rico Liang as chief product officer, and updates from Parexel, Dignify and GRO

BioCentury ISSN 1097-7201